Trial Profile
A single ascending dose (SAD) study of ORC-13661 in healthy volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Oct 2018
Price :
$35
*
At a glance
- Drugs ORC-13661 (Primary)
- Indications Hearing loss
- Focus Adverse reactions
- 11 Oct 2018 New trial record
- 30 Aug 2018 Results presented in an Oricula Therapeutics media release.